V K Morris1, F A San Lucas2, M J Overman3, C Eng3, M P Morelli3, Z-Q Jiang3, R Luthra4, F Meric-Bernstam5, D Maru6, P Scheet7, S Kopetz8, E Vilar9. 1. Department of Cancer Medicine, The University of Texas-MD Anderson Cancer Center, Houston. 2. Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, USA. 3. Department of Gastrointestinal Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston. 4. Department of Hematopathology, The University of Texas-MD Anderson Cancer Center, Houston. 5. Department of Surgical Oncology, The University of Texas-MD Anderson Cancer Center, Houston. 6. Department of Pathology, The University of Texas-MD Anderson Cancer Center, Houston. 7. Department of Epidemiology, The University of Texas-MD Anderson Cancer Center, Houston. 8. Department of Gastrointestinal Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston; Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, USA. 9. Department of Gastrointestinal Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston; Clinical Cancer Prevention, The University of Texas-MD Anderson Cancer Center, Houston. Electronic address: evilar@mdanderson.org.
Abstract
BACKGROUND: KRAS mutations in codons 12 and 13 are present in ∼40% of all colorectal cancers (CRC). Activating mutations in codons 61 and 146 of KRAS and in codons 12, 13, and 61 of NRAS also occur but are less frequent. The clinicopathologic features and gene expression profiles of this latter subpopulation of RAS-mutant colorectal tumors have not yet been clearly defined but in general are treated similarly to those with KRAS 12 or 13 mutations. PATIENTS AND METHODS: Records of patients with metastatic CRC (mCRC) treated at MD Anderson Cancer Center between December 2000 and August 2012 were reviewed for RAS (KRAS or NRAS) and BRAF mutation status, clinical characteristics, and survival outcomes. To study further with an independent cohort, data from The Cancer Genome Atlas were analyzed to define a gene expression signature for patients whose tumors feature these atypical RAS mutations and explore differences with KRAS 12/13-mutated colorectal tumors. RESULTS: Among the 484 patients reviewed, KRAS 12/13, KRAS 61/146, NRAS, and BRAF mutations were detected in 47.7%, 3.0%, 4.1%, and 7.4%, respectively, of patients who were tested for each of these aberrations. Lung metastases were more common in both the KRAS 12/13-mutated and atypical RAS-mutated cohorts relative to patients with RAS/BRAF wild-type tumors. Gene expression analyses revealed similar patterns regardless of the site of RAS mutation, and in silico functional algorithms predicted that KRAS and NRAS mutations in codons 12, 13, 61, and 146 alter the protein function and drive tumorgenesis. CONCLUSIONS: Clinicopathologic characteristics, survival outcomes, functional impact, and gene expression profiling were similar between patients with KRAS 12/13 and those with NRAS or KRAS 61/146-mutated mCRC. These clinical and bioinformatic findings support the notion that colorectal tumors driven by these RAS mutations are phenotypically similar.
BACKGROUND:KRAS mutations in codons 12 and 13 are present in ∼40% of all colorectal cancers (CRC). Activating mutations in codons 61 and 146 of KRAS and in codons 12, 13, and 61 of NRAS also occur but are less frequent. The clinicopathologic features and gene expression profiles of this latter subpopulation of RAS-mutant colorectal tumors have not yet been clearly defined but in general are treated similarly to those with KRAS 12 or 13 mutations. PATIENTS AND METHODS: Records of patients with metastatic CRC (mCRC) treated at MD Anderson Cancer Center between December 2000 and August 2012 were reviewed for RAS (KRAS or NRAS) and BRAF mutation status, clinical characteristics, and survival outcomes. To study further with an independent cohort, data from The Cancer Genome Atlas were analyzed to define a gene expression signature for patients whose tumors feature these atypical RAS mutations and explore differences with KRAS 12/13-mutated colorectal tumors. RESULTS: Among the 484 patients reviewed, KRAS 12/13, KRAS 61/146, NRAS, and BRAF mutations were detected in 47.7%, 3.0%, 4.1%, and 7.4%, respectively, of patients who were tested for each of these aberrations. Lung metastases were more common in both the KRAS 12/13-mutated and atypical RAS-mutated cohorts relative to patients with RAS/BRAF wild-type tumors. Gene expression analyses revealed similar patterns regardless of the site of RAS mutation, and in silico functional algorithms predicted that KRAS and NRAS mutations in codons 12, 13, 61, and 146 alter the protein function and drive tumorgenesis. CONCLUSIONS: Clinicopathologic characteristics, survival outcomes, functional impact, and gene expression profiling were similar between patients with KRAS 12/13 and those with NRAS or KRAS 61/146-mutated mCRC. These clinical and bioinformatic findings support the notion that colorectal tumors driven by these RAS mutations are phenotypically similar.
Authors: Yu Imamura; Teppei Morikawa; Xiaoyun Liao; Paul Lochhead; Aya Kuchiba; Mai Yamauchi; Zhi Rong Qian; Reiko Nishihara; Jeffrey A Meyerhardt; Kevin M Haigis; Charles S Fuchs; Shuji Ogino Journal: Clin Cancer Res Date: 2012-07-02 Impact factor: 12.531
Authors: Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg Journal: N Engl J Med Date: 2008-10-23 Impact factor: 91.245
Authors: Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier Journal: N Engl J Med Date: 2009-04-02 Impact factor: 91.245
Authors: Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt Journal: N Engl J Med Date: 2009-02-05 Impact factor: 91.245
Authors: Humaid O Al-Shamsi; Jeremy Jones; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Reham Abdel-Wahab; Ahmed O S Abousamra; Kenna R Shaw; Lianchun Xiao; Manal M Hassan; Benjamin R Kipp; Scott Kopetz; Amr S Soliman; Robert R McWilliams; Robert A Wolff Journal: J Gastrointest Oncol Date: 2016-12
Authors: Christopher Ritchie; Andrew Mack; Logan Harper; Ayna Alfadhli; Philip J S Stork; Xiaolin Nan; Eric Barklis Journal: Cancer Genomics Proteomics Date: 2017 Jul-Aug Impact factor: 4.069
Authors: Andrew Rankin; Samuel J Klempner; Rachel Erlich; James X Sun; Axel Grothey; Marwan Fakih; Thomas J George; Jeeyun Lee; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Siraj M Ali; Alexa B Schrock Journal: Oncologist Date: 2016-09-28
Authors: Frank A Sinicrope; Qian Shi; Carmen J Allegra; Thomas C Smyrk; Stephen N Thibodeau; Richard M Goldberg; Jeffrey P Meyers; Kay L Pogue-Geile; Greg Yothers; Daniel J Sargent; Steven R Alberts Journal: JAMA Oncol Date: 2017-04-01 Impact factor: 31.777